强生公司最新披露的临床研究显示,其研发的创新型疗法Erda-Idrs(原代号Tar-210)在针对中危非肌层浸润性膀胱癌的首次人体试验中取得显著成效。该结果标志着这一候选药物在泌尿系统肿瘤治疗领域迈出关键一步,为后续临床开发奠定重要基础。
强生公司最新披露的临床研究显示,其研发的创新型疗法Erda-Idrs(原代号Tar-210)在针对中危非肌层浸润性膀胱癌的首次人体试验中取得显著成效。该结果标志着这一候选药物在泌尿系统肿瘤治疗领域迈出关键一步,为后续临床开发奠定重要基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.